Elie Dolgin | Jun 15, 2009 | 4 min read
The excitement surrounding cellular reprogramming and the possibility of federal funding for human embryonic stem cell (ESC) research in the US could be overshadowing another promising therapeutic source of stem cells: those derived via parthenogenesis, some researchers say. But later-developed techniques such as induced pluripotent stem cells (iPSCs) could make this approach obsolete, and the final draft of the stem cell guidelines, due out by July 7, might put the nail in the parthenote coffin